Lupin Pharmaceuticals Inc. 2024-05-22 Health serious FDA
Health · FDA · Recall #FDA-D-0496-2024
Cefdinir for Oral Suspension USP 250 mg/5 mL (60 mL when reconstituted), 60 mL bottle, Rx… Recall
Issued May 22, 2024 · Lupin Pharmaceuticals Inc.
In May 2024, Lupin Pharmaceuticals Inc. recalled the Cefdinir for Oral Suspension USP 250 mg/5 mL (60 mL when reconstituted), 60 mL bottle, Rx…, a serious health recall reported by the FDA. Affected owners are eligible for a voluntary. Here is what the hazard is and exactly what to do about it.
Compiled by Maya Ellison, RecallCheckr
What this means for you
Presence of foreign substance: Product complaint of foreign material in reconstituted bottle.
What you should do
- 1 Stop using Cefdinir for Oral Suspension USP 250 mg/5 mL (60 mL when reconstituted), 60 mL bottle, Rx… right away.
- 2 Set it aside where it won't be used by mistake.
- 3 Contact Lupin Pharmaceuticals Inc. to arrange your voluntary. See the official notice below for contact details.
- 4 Keep the product until your remedy is fully processed. You may need it.
Official remedy (Voluntary):
Recall details
- Brand
- Lupin Pharmaceuticals Inc.
- Category
- Health
- Recall date
- May 22, 2024
- Units affected
- Not reported
- Sold at
- USA nationwide
- Recall number
- FDA-D-0496-2024
- Made in
- United States
- Issuing agency
- FDA
In context
- Lupin Pharmaceuticals Inc. has 19 recalls in our database, including 1 rated Critical.
- We're tracking 3,576 Health recalls in our database.
- This is the 737th Health recall we've logged in 2024.